AZN vs BDRX

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of 2/9, indicating severe operational and financial distress. Despite a strong current and quick ratio suggesting short-term liquidity, the company is unprofitable across all margins, with deeply negative ROE and ROA. Valuation metrics are largely undefined due to lack of earnings and revenue data, while the stock has lost nearly all value over the past year. Insider sentiment is neutral-to-weak, and there is no analyst coverage or dividend support, amplifying risk.